Cite
HARVARD Citation
Park, K. et al. (n.d.). 1379TiPPhase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor. Annals of oncology. p. . [Online].